Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF) trades at $0.19 with AI Score 63/100 (Grade B+). Sihuan Pharmaceutical Holdings Group Ltd. Market cap: $1.69B, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for SHPHF: SHPHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SHPHF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SHPHF: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF) Healthcare & Pipeline Overview
Sihuan Pharmaceutical Holdings Group Ltd., based in Hong Kong, develops, manufactures, and markets pharmaceutical products in China, focusing on oncology, metabolic diseases, and medical aesthetics. With a diverse portfolio and a presence in medical beauty, the company navigates a competitive landscape in the specialty and generic drug market.
What Is the Investment Thesis for SHPHF?
Sihuan Pharmaceutical presents a mixed investment case. The company's presence in multiple therapeutic areas, including oncology and metabolic diseases, offers diversification. The company's gross margin of 66.3% indicates pricing power. However, a negative profit margin of -3.8% and a high P/E ratio of -142.40 raise concerns about profitability and valuation. The dividend yield of 0.77% provides a modest return to investors. Growth catalysts include expansion in the medical beauty sector and potential new drug approvals. Investors should carefully weigh the growth opportunities against the financial risks and market competition.
Based on FMP financials and quantitative analysis
SHPHF Key Highlights
- Market capitalization of $1.71 billion, reflecting its size and market value within the pharmaceutical industry.
- Gross margin of 66.3%, indicating strong pricing power and efficient cost management in its manufacturing processes.
- Dividend yield of 0.77%, providing a modest income stream for investors.
- Negative P/E ratio of -142.40, signaling current losses and potentially overvaluation.
- Beta of 1.13, suggesting slightly higher volatility compared to the overall market.
Who Are SHPHF's Competitors?
SHPHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| APNHY Aspen Pharmacare Holdings Limited | $8.77 | +0.00% | $3.89B | 50 |
| ARSUF Fagron N.V. | $26.53 | +0.00% | $1.95B | 54 |
| CASBF CanSino Biologics Inc. | $3.10 | +0.00% | $1.08B | — |
| CHSYF China Medical System Holdings Limited | $1.35 | +0.00% | $3.27B | 53 |
| CURLF Curaleaf Holdings, Inc. | $10.43 | +0.38% | $2.76B | 53 |
| ALVO Alvotech | $4.44 | +5.21% | $1.39B | 69 |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SHPHF's Key Strengths?
- Diverse product portfolio across multiple therapeutic areas.
- Established manufacturing capabilities for pharmaceuticals and medical instruments.
- Presence in the growing Chinese pharmaceutical market.
- Integration across various healthcare services.
What Are SHPHF's Weaknesses?
- Negative profit margin.
- High P/E ratio.
- Reliance on the Chinese market.
- Exposure to regulatory risks in the pharmaceutical industry.
What Could Drive SHPHF Stock Higher?
- Potential new drug approvals in oncology and metabolic diseases.
- Expansion in the medical beauty market.
- Geographic expansion within China.
- Strategic partnerships and acquisitions to expand product portfolio.
- Increased focus on generic drug manufacturing.
What Are the Key Risks for SHPHF?
- Intense competition from domestic and international pharmaceutical companies.
- Pricing pressures from generic drug manufacturers.
- Changes in government regulations and healthcare policies.
- Economic slowdown in China affecting demand for pharmaceutical products.
- Risks associated with operating in the OTC market, including limited liquidity and disclosure.
What Are the Growth Opportunities for SHPHF?
- Expansion in Medical Beauty Products: Sihuan's involvement in the investment and sale of medical beauty products represents a significant growth opportunity. The medical aesthetics market in China is experiencing rapid growth, driven by increasing disposable incomes and a growing emphasis on personal appearance. By leveraging its existing pharmaceutical infrastructure and distribution channels, Sihuan can capitalize on this trend and increase revenue streams. The Chinese medical aesthetics market is projected to reach billions of dollars in the coming years, offering substantial growth potential for Sihuan.
- New Drug Development and Approvals: Sihuan's research and development efforts in oncology, metabolic diseases, and other therapeutic areas could lead to the development and approval of new drugs. Successful drug approvals can significantly boost revenue and market share. The company's pipeline of potential new drugs represents a key growth driver. The timeline for realizing this growth opportunity depends on the success of clinical trials and regulatory approvals, but it could materialize within the next 3-5 years.
- Geographic Expansion within China: While Sihuan already operates in China, there is potential for further geographic expansion within the country. By targeting underserved regions and expanding its distribution network, the company can reach new customers and increase sales. This growth opportunity is particularly relevant in rural areas where access to healthcare is limited. The timeline for this expansion depends on the company's strategic priorities and investment decisions, but it could be implemented over the next 2-3 years.
- Strategic Partnerships and Acquisitions: Sihuan could pursue strategic partnerships or acquisitions to expand its product portfolio, gain access to new technologies, or enter new markets. Collaborating with other pharmaceutical companies or acquiring smaller, innovative firms can accelerate growth and enhance competitiveness. This growth opportunity is contingent on identifying suitable partners or acquisition targets and successfully integrating them into the company's operations. The timeline for this strategy is variable and depends on market conditions and deal availability.
- Increased Focus on Generic Drug Manufacturing: With the rising demand for affordable healthcare, Sihuan can capitalize on its generic drug manufacturing capabilities. By increasing production efficiency and expanding its generic drug portfolio, the company can cater to the growing demand for cost-effective medications. This strategy aligns with the Chinese government's efforts to promote generic drug usage and reduce healthcare costs. The timeline for this growth opportunity is relatively short, as it primarily involves optimizing existing manufacturing processes and expanding product lines.
What Opportunities Does SHPHF Have?
- Expansion in the medical beauty market.
- New drug development and approvals.
- Geographic expansion within China.
- Strategic partnerships and acquisitions.
What Threats Does SHPHF Face?
- Intense competition from domestic and international players.
- Pricing pressures from generic drug manufacturers.
- Changes in government regulations and healthcare policies.
- Economic slowdown in China.
What Are SHPHF's Competitive Advantages?
- Established presence in the Chinese pharmaceutical market.
- Diverse product portfolio across multiple therapeutic areas.
- Manufacturing capabilities for both pharmaceutical and medical instruments.
- Integration across various healthcare services, including hospital management.
What Does SHPHF Do?
Founded in 2001 and headquartered in Wanchai, Hong Kong, Sihuan Pharmaceutical Holdings Group Ltd. operates as an investment holding company with a focus on the pharmaceutical sector in the People's Republic of China. The company's core business revolves around the research and development, manufacture, marketing, and sale of pharmaceutical products. Sihuan Pharmaceutical offers a diverse portfolio of drugs targeting various therapeutic areas, including oncology, metabolic diseases, and digestive system disorders. Beyond pharmaceuticals, Sihuan has expanded its operations to include the investment and sale of medical beauty products, the manufacture of medical instruments, property investment, construction for medical projects, and project preparation for pharmaceutical product manufacturing. The company also provides information support, general hospital services, hospital management, biotechnology promotion, and medical aesthetic research and development services, demonstrating a diversified approach within the healthcare industry. Sihuan Pharmaceutical's operations are primarily concentrated in China, reflecting its strategic focus on the Chinese pharmaceutical market.
What Products and Services Does SHPHF Offer?
- Researches and develops pharmaceutical products.
- Manufactures a range of drugs for various therapeutic areas.
- Markets and sells pharmaceutical products in China.
- Invests in and sells medical beauty products.
- Manufactures medical instruments.
- Invests in properties and undertakes construction for medical projects.
- Provides information support and hospital management services.
- Engages in biotechnology promotion and medical aesthetic R&D.
How Does SHPHF Make Money?
- Develops and manufactures pharmaceutical products.
- Generates revenue through the sale of these products in the Chinese market.
- Expands revenue streams through medical beauty products and services.
- Invests in related healthcare ventures like hospital management.
What Industry Does SHPHF Operate In?
Sihuan Pharmaceutical operates in the competitive Chinese pharmaceutical market, which is characterized by increasing demand for generic and specialty drugs. The market is driven by an aging population, rising healthcare expenditure, and government initiatives to improve access to healthcare. The company faces competition from both domestic and international players, including companies like APNHY (Astellas Pharma) and ARSUF (Arbutus Biopharma), requiring Sihuan to innovate and differentiate its product offerings to maintain market share. The Chinese pharmaceutical market is expected to continue growing, presenting opportunities for Sihuan to expand its presence.
Who Are SHPHF's Key Customers?
- Hospitals and healthcare institutions in China.
- Pharmacies and drug retailers.
- Patients requiring prescription medications.
- Consumers of medical beauty products.
SHPHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
SHPHF Latest News
No recent news available for SHPHF.
SHPHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SHPHF.
Price Targets
Wall Street price target analysis for SHPHF.
SHPHF MoonshotScore
What does this score mean?
The MoonshotScore rates SHPHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Weicheng Guo
CEO
Weicheng Guo serves as the CEO of Sihuan Pharmaceutical Holdings Group Ltd. His background includes extensive experience in the pharmaceutical industry, with a focus on strategic development and operational management. He has been instrumental in guiding the company's growth and expansion in the Chinese market. His leadership is focused on driving innovation and enhancing the company's competitive position.
Track Record: Under Weicheng Guo's leadership, Sihuan Pharmaceutical has expanded its product portfolio and strengthened its market presence in China. He has overseen key strategic initiatives, including investments in research and development and expansion into the medical beauty sector. His tenure has been marked by efforts to improve operational efficiency and enhance shareholder value.
SHPHF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Sihuan Pharmaceutical Holdings Group Ltd. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, potentially increasing investment risk compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier is typically reserved for companies with limited operations, distressed financials, or those that choose not to comply with higher reporting standards. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility and difficulty in trading.
- Potential for delisting or suspension of trading.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Limited regulatory oversight compared to major exchanges.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Analyze the company's capital structure and debt levels.
- Monitor news and regulatory filings for any red flags.
- Consult with a financial advisor before investing.
- Established history of operations in the pharmaceutical industry.
- Presence in multiple therapeutic areas.
- Manufacturing capabilities for pharmaceuticals and medical instruments.
- CEO with experience in the pharmaceutical sector.
- Dividend yield of 0.77%.
Sihuan Pharmaceutical Holdings Group Ltd. Healthcare Stock: Key Questions Answered
What does Sihuan Pharmaceutical Holdings Group Ltd. do?
Sihuan Pharmaceutical Holdings Group Ltd. is a Hong Kong-based pharmaceutical company that focuses on the research, development, manufacturing, and sale of pharmaceutical products in China. It operates across multiple therapeutic areas, including oncology, metabolic diseases, and digestive system disorders. The company also has a presence in the medical beauty sector, offering related products and services. Sihuan's business model involves developing and manufacturing drugs, marketing them to hospitals, pharmacies, and patients in China, and expanding its revenue streams through its medical beauty segment.
What do analysts say about SHPHF stock?
Analyst coverage of SHPHF is limited due to its OTC listing. Key valuation metrics include a negative P/E ratio, reflecting current losses, and a gross margin of 66.3%, indicating strong pricing power. Growth considerations include the company's expansion in the medical beauty market and potential new drug approvals. Investors should conduct their own due diligence and consider the risks associated with investing in an OTC-listed company with limited financial disclosure.
What are the main risks for SHPHF?
The main risks for Sihuan Pharmaceutical include intense competition in the Chinese pharmaceutical market, pricing pressures from generic drug manufacturers, and potential changes in government regulations and healthcare policies. The company also faces risks associated with its OTC listing, including limited liquidity and disclosure. Additionally, an economic slowdown in China could negatively impact demand for pharmaceutical products. Investors should carefully consider these risks before investing in SHPHF.
What are the key factors to evaluate for SHPHF?
Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF) holds an AI score of 63/100 (moderate). Not financial advice.
How frequently does SHPHF data refresh on this page?
SHPHF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SHPHF's recent stock price performance?
Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio across multiple therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SHPHF overvalued or undervalued right now?
Valuing Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SHPHF?
Before investing in Sihuan Pharmaceutical Holdings Group Ltd. (SHPHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to OTC listing.
- Financial data based on available public information.